Elexacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector used as part of combination therapy for treating cystic fibrosis (CF) in patients with at least one F508del mutation in the CFTR gene. It works by improving the folding and trafficking of the defective CFTR protein to the cell surface, thereby restoring chloride ion transport across epithelial cells.
Elexacaftor is not used as a monotherapy—it is co-administered with tezacaftor (another corrector) and ivacaftor (a potentiator) in the triple combination therapy branded as Trikafta®.
Indications include:
∙ Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation in the CFTR gene
∙ Approved by FDA and EMA as part of triple-combination therapy
Elexacaftor is a synthetic small molecule with a complex structure containing multiple functional groups. Impurities may arise during multi-step chemical synthesis, including amide formation, heterocyclic coupling, and alkylation steps, as well as from degradation under heat, moisture, or light.
Because it is used in chronic treatment of a genetic disorder, impurity levels are tightly regulated per ICH Q3A/B, USP, EP, and FDA guidelines.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Elexacaftor is used in combination with tezacaftor and ivacaftor to treat cystic fibrosis (CF) in patients with at least one copy of the F508del mutation, the most common CFTR mutation.
It acts as a CFTR corrector, helping misfolded CFTR proteins reach the cell surface, thereby restoring chloride transport in epithelial tissues.
No. Elexacaftor is always used as part of a triple-combination therapy with tezacaftor and ivacaftor.
Elexacaftor is generally stable under controlled conditions, but sensitive to moisture and light. It should be stored in its original container at room temperature, protected from excessive humidity and heat.
